Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,289)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06045091 | To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL | recruiting | Early Phase 1 | 18 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04613557 | Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma(IMMUNICY-1) | active not recruiting | Phase 1 | 18 | Celyad Oncology SAINDUSTRY | 2 | Aug 31, 2023 |
| clinicaltrials |
| NCT03127761 | Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma | recruiting | — | 544 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 30, 2023 | clinicaltrials |
| NCT05996367 | Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma | recruiting | N/A | 50 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05968417 | Myeloma Novel Drug Discovery Ver 1.2(DISCO) | recruiting | — | 250 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05965115 | The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study(CHAPERONE) | recruiting | — | 10,000 | Shanghai Zhongshan HospitalOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05967949 | A Retrospective Clinical Study on the First-line Maintenance Treatment of PTCL With Chidamide. | recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05970198 | Helical Tomotherapy in Multiple Myeloma | recruiting | N/A | 58 | Fuling ZhouOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05846750 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 59 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05931263 | A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL | recruiting | Phase 3 | 104 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2023 | clinicaltrials |
| NCT05909826 | Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM(KMM-KCd) | not yet recruiting | Phase 2 | 49 | Dong-A University HospitalOTHER | 0 | Jun 18, 2023 | clinicaltrials |
| NCT05899621 | A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL | recruiting | — | 332 | Ruijin HospitalOTHER | 1 | Jun 12, 2023 | clinicaltrials |
| NCT05846763 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study | recruiting | — | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03948035 | Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | active not recruiting | Phase 3 | 576 | Wuerzburg University HospitalOTHER | 2 | May 6, 2023 | clinicaltrials |
| NCT05831865 | Frontline of ASCT in High-risk DLBCL(Essential) | recruiting | — | 175 | Peking University People's HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05840575 | Investigating Cognitive Impairment in Young Patients With Cancer Prospectively(MyBrain) | recruiting | — | 100 | Rigshospitalet, DenmarkOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04006561 | Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost | recruiting | — | 36 | Chang Gung Memorial HospitalOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05833893 | Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma | recruiting | Phase 2 | 10 | Chinese PLA General HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04526834 | Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma(CERTAIN) | active not recruiting | Phase 1 | 21 | Tessa TherapeuticsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03969693 | Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation | not yet recruiting | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04920617 | DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(VITALIZE) | recruiting | Phase 2 | 102 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 10 | Apr 7, 2023 | clinicaltrials |
| NCT03688451 | Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma | active not recruiting | Phase 2 | 20 | Tahir LatifOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05521802 | A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 92 | Shanghai AbelZeta Ltd.INDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05746858 | Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL) (MIMOSA)(MIMOSA) | not yet recruiting | — | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04088422 | Cell Free DNA in Mature B-cell Lymphoma | recruiting | — | 320 | Ruijin HospitalOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT05659628 | CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL | recruiting | Phase 1 | 24 | Ningbo No. 1 HospitalOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT05594797 | Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM | recruiting | Phase 2 | 100 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT03064867 | Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 65 | Molly GalloglyOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT05600660 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 28 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04922567 | Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 289 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05581875 | A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory | not yet recruiting | Phase 1 / Phase 2 | 48 | Hellenic Society of HematologyOTHER | 0 | Oct 17, 2022 | clinicaltrials |
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning(HLA) | recruiting | Phase 2 | 114 | University of LiegeOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05552937 | Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL | recruiting | Phase 2 | 50 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT03742297 | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | active not recruiting | Phase 3 | 462 | PETHEMA FoundationOTHER | 1 | Sep 14, 2022 | clinicaltrials |
| NCT02415413 | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 90 | PETHEMA FoundationOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT05528055 | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors | recruiting | Phase 1 | 122 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 6, 2022 | clinicaltrials |
| NCT04442412 | Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy(FIL_PREVID) | recruiting | Phase 3 | 430 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT05518383 | B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | recruiting | Phase 4 | 300 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02859402 | Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas(RRTCLAlloSCT) | recruiting | Phase 2 | 34 | Keimyung University Dongsan Medical CenterOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05506410 | A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma | recruiting | — | 100 | Zhengzhou UniversityOTHER | 1 | Aug 18, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT02477878 | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | active not recruiting | Phase 1 | 10 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03301168 | Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 120 | Bellicum PharmaceuticalsINDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05429515 | Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury | not yet recruiting | Phase 4 | 50 | Peking Union Medical College HospitalOTHER | 0 | Jun 23, 2022 | clinicaltrials |
| NCT05338931 | Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 82 | AbClonINDUSTRY | 1 | May 26, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05353907 | Dual-Energy Computed Tomography for Improving Imaging Assessment of Multiple Myeloma(DECIMA) | not yet recruiting | — | 78 | Guy's and St Thomas' NHS Foundation TrustOTHER | 0 | Apr 29, 2022 | clinicaltrials |
| NCT05347641 | Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | not yet recruiting | Phase 2 | 23 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05298293 | Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma(EMILY) | not yet recruiting | N/A | 160 | WepromOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03161223 | Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma | recruiting | Phase 1 / Phase 2 | 148 | University of VirginiaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Sep 21, 2023source: clinicaltrials